OVERVIEW:
Backed by a strong legacy of navigating complex challenges over the past four decades, the company maintains a forward-looking stance and remains well-positioned to pursue sustainable long-term growth. We look ahead and push ourselves to re-innovate and Decipher the Future by grasping the opportunity while being introspective and realising and building on our core strengths.
INDUSTRY STRUCTURE AND DEVELOPMENTS:
Companies across the globe have consolidated and are capitalizing on the opportunities that they come across in the new geopolitical turmoil. Your Company has also strived to utilise its investment plans and close collaboration with customers, banks, financial institutions, suppliers and employees and focus on costs, efficiency and initiatives for the long term. The numbers of the company may have declined today compared to the earlier year, but the continued efforts and initiates have the potential to yield creditable market share with the potential to significantly enhance its financial performance in the future. With the USA now adopting a firm stance, we expect businesses to stabilise and growth to return to the country thereby furling fresh demand for expansions in the market.
Operating in India and USA with a vision to expand further to other promising countries, the long-term outlook continues to remain positive. The management is continuously experimenting with the business and operating models without any presumptions and the series of initiatives set in motion, to reconfigure the Company aimed at sustainable growth whilst focusing its efforts on securing contracts, completing key collaborations for growth while developing integrated digital channels to enhance the values of the company and its subsidiary to be an agile player geared up for sustained growth in the coming years, are likely to yield result soon.
OPPORTUNITIES AND THREATS:
The company has consistently pursued strategic partnerships and, through its Promoter Director, has engaged with multiple potential targets. While these efforts have not yet resulted in finalized agreements, the Board of Directors continues to support the Promoters initiatives and remains optimistic about achieving success in securing joint ventures or acquisitions in the market in the near term. The Company is focussing more on the Information technology side of the business in the US market with very high scope of expansions and scalability. While the pharmaceutical industry sees a growth pattern in the recent years, there is all likelihood of a slowdown due to major Geopolitical issues that have recently taken centre stage. Further, due to the economic pressure envisaged due to the withdrawal of the Pharmaceutical supplies across the globe, pricing and anti-dumping will become the key concern for the pharmaceutical sector in the coming years adding to the concern and eminent threat of decline in the margins because of increasing competition from smaller new entrants, Generic medicine pricing & policies of various Governments.
SEGMENT -WISE OR PRODUCT WISE PERFORMANCE:
Revenues - Standalone
During the year under review, the Company on a standalone basis has recorded an income of Rs. 87.60 Lakhs and incurred a loss of Rs. 44.02 Lakhs as against the income of Rs. 355.15 Lakhs and profit of Rs. 2.34 Lakhs respectively in the previous financial year ending 31.03.2024.
Revenues - Consolidated
During the year under review, the Company on a consolidated basis has recorded an income of Rs. 2,393.07 Lakhs and incurred a loss of Rs. 508.02 Lakhs as against the income of Rs. 3,629.51 Lakhs and loss of Rs. 167.55 Lakhs respectively in the previous financial year ending 31.03.2024.
Standalone |
Consolidated |
|||
Segment |
Revenue generated in FY 2024 - 25 (Amount in Lakhs) |
Revenue generated in FY 2023 - 24 (Amount in Lakhs) |
Revenue generated in FY 2024 - 25 (Amount in Lakhs) |
Revenue generated in FY 2023 - 24 (Amount in Lakhs) |
Manufacturing and Trading of Pharmaceutical drugs |
68.60 |
327.33 |
68.60 |
327.33 |
Consultancy Services |
16.72 |
25.83 |
2192.65 |
3260.53 |
The details of the financial performance of the Company are comprised in the Balance Sheet, Profit and Loss Account and other financial statements which are annexed hereto along with the Directors and the Auditors Report.
INTERNAL CONTROL SYSTEMS AND THEIR ADEQUACY:
The Company has an adequate internal control system which commensurate with the size and nature of its business. The internal control system is being supported by internal audits, regular reviews by management to ensure reliability of financial and all other records to prepare financial statements and other data. Further the Audit Committee of the Board review the findings and recommendations of the internal audit and suitable implementations are affected.
RISK MANAGEMENT SYSTEM:
The company manages our business risk through strict compliance and internal control system.
RISK AND CONCERNS:
Decipher Labs Limited does a regular and stringent monitoring of its business activities to identify, evaluate and resolve risks. The top management of the Company and the Board are involved in monitoring of risk assessment and mitigation, thus ensuring a quick resolution mechanism.
In line with our stated philosophy and strategy, the company will continue to pursue various options to achieve growth while trying to reduce the cost and focus more on marketing tie-ups to expand its market reach.
Your Company has adequate internal control systems commensurate with the size of its operations for the purpose of exercising adequate controls on day-to-day operations of the Company and is at present involved in sourcing the products and services through third party facilities in various locales.
The details of the financial performance of the Company are comprised in the Balance Sheet, Profit and Loss Account and other financial statements which are annexed hereto along with the Directors and the Auditors Report for the financial year 2024-2025.
OUTLOOK:
The Financial Year 2025 has been a period of strategic consolidation, marked by close monitoring of global geopolitical developments. During this time, the company, through its Promoter Director, actively explored collaborative opportunities and divisional expansion aimed at enhancing overall value. While various challenges have emerged along the growth trajectory, the company remains confident in its ability to navigate these obstacles and deliver performance that exceeds its previous benchmarks in the near future.
The company has been served with an Order issued by the Quasi-Judicial Authority, SEBI, dated July 31,2025. This Order prohibits the company, its Promoter, and its Director from engaging with capital markets and imposes unwarranted penalties on the Directors, in addition to restricting their market holdings based on the findings of an investigation. Although the investigation revealed no involvement of the management or the company, the Securities and Exchange Board of India (SEBI) has imposed severe penalties, including the debarment of the company and its Directors for selling portions of their equity shares in the market.
Management contends that this Order represents the most stringent possible outcome arising from an investigation that has not presented any evidence of any misconduct by the companys management, aside from the liquidation of portions of their longtime shareholdings. The investigation also confirmed, in its report, that the management was not involved in any intended manipulations in the market. Disregarding the extensive service history of the Director/s to the company, numerous unjustified, unproven assumptions have been made regarding the Director/s intentions and an unjust order has been passed.
As part of its consolidation and expansion strategy, the company had been actively pursuing collaborations, joint ventures, and acquisitions in both the United States and India. Following an order issued by SEBI, and as discussed in the Board meeting, the company has realigned its focus in accordance with regulatory guidance.
Drawing on over four decades of resilience and adaptability, the company remains confident in its ability to deliver sustained long-term growth.
The company had been, as part of the consolidation and expansion targets, aggressively pursuing collaborations and Joint Ventures and Takeovers in USA and in India which has now officially been paused as approved in the Board meeting dated August 14, 2025 subsequent to the order received from SEBI.Nevertheless, having successfully navigated numerous challenges over the past four decades, the company remains optimistic about its ability to achieve long-term improvement.
DISCLOSURE OF ACCOUNTING TREATMENT:
The Company has not carried out any treatment different from that prescribed in Accounting Standards.
DETAILS OF SIGNIFICANT CHANGES:
Particulars |
F.Y 2024-25 |
F.Y 2023-24 |
% of changes |
Remarks |
Debtors Turnover |
0.41 |
19.94 |
-98% |
Outstanding balance received from the debtors |
Inventory Turnover |
- |
- |
-- |
|
Interest Coverage Ratio |
- |
- |
- - |
|
Current Ratio |
0.47 |
1.04 |
- 55% |
Due to decrease in sales. |
Debt Equity Ratio |
- |
- |
-- |
|
Operating Profit Margin (%) |
-0.52 |
0.01 |
-7925% |
Due to decrease in sales. |
Net Profit Margin (%) |
-0.52 |
0.01 |
-7925% |
Due to decrease in sales. |
Return on Net-worth |
-0.05 |
0.00 |
-7843% |
Due to decrease in sales |
There is change in net worth as compared to the immediately previous financial year.
HUMAN RESOURCES:
The company is in the process of expansion of its operations and with time will need to expand the man power which had previously come down during consolidation. There is a conscious effort by the Company to build diversity in the workforce. The company through its subsidiary has sufficient manpower.
CAUTIONARY STATEMENT:
Some of the statements in this Management Discussion & Analysis, describing the Companys objectives, projections, estimates and expectations may be "forward looking statement" within the meaning of applicable laws and regulations. Actual results might differ substantially from those expressed or implied. Important developments that could affect the Companys operation including changes in the industry structure, significant changes in political and economic environment in India, tax laws, import duties, litigation and labour relations. The Company does not undertake endeavors to update these statements.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.